

Having trouble finding Acyclovir at your pharmacy? Learn why this antiviral medication is hard to find in 2026 and what you can do about it.
You went to the pharmacy, handed over your prescription, and heard the words no patient wants to hear: "We don't have it in stock." If you've been trying to fill an Acyclovir prescription recently, you may have run into empty shelves and long wait times. You're not imagining it — and you're definitely not alone.
Acyclovir is one of the most widely prescribed antiviral medications in the United States. Millions of people depend on it for conditions like genital herpes, shingles, chickenpox, and cold sores. So why is it so hard to find in 2026?
In this article, we'll break down what Acyclovir is, why pharmacies are running low, and — most importantly — what you can do to get the medication you need.
Acyclovir is a generic antiviral medication that treats infections caused by herpes viruses. You might also know it by the brand name Zovirax. It belongs to a class of drugs called nucleoside analog antivirals, and it works by stopping the virus from multiplying in your body.
Doctors prescribe Acyclovir for several conditions, including:
Acyclovir comes in several forms: oral capsules (200 mg), tablets (400 mg and 800 mg), liquid suspension, topical cream and ointment, and an injectable form used in hospitals. For most patients, the oral tablets are what they're trying to find at the pharmacy.
To learn more about how this medication works in your body, check out our guide on how Acyclovir works.
There's no single reason Acyclovir is difficult to find — it's a combination of factors that have created a perfect storm of supply problems. Here are the main reasons:
The injectable (IV) form of Acyclovir has been in and out of shortage since 2020. While the oral forms are generally more available, supply chain disruptions at manufacturing plants can create ripple effects. When one manufacturer has a production issue, the remaining suppliers can't always pick up the slack fast enough.
The FDA and ASHP (American Society of Health-System Pharmacists) have tracked these shortages closely. As of late 2024, the IV shortage was improving thanks to increased production from manufacturers like Fresenius Kabi, but the situation remains fragile.
Demand for Acyclovir has risen steadily. More patients are being diagnosed with herpes simplex and herpes zoster, partly because of better testing and awareness. Telehealth has also made it easier for patients to get prescriptions, increasing the volume of prescriptions hitting pharmacies.
Because Acyclovir is an older, inexpensive generic drug, the profit margins are slim. That means fewer pharmaceutical companies want to produce it. When only a handful of manufacturers supply the entire country, even small disruptions can cause widespread shortages.
Even when Acyclovir is available from manufacturers, it doesn't always reach every pharmacy evenly. Large chain pharmacies tend to get priority from distributors, while smaller independent pharmacies may face delays. Your local pharmacy might be out of stock even though a pharmacy across town has plenty.
For the latest information on availability, see our Acyclovir shortage update for 2026.
The good news is that you have options. Here's what we recommend:
The fastest way to find Acyclovir in stock near you is to use Medfinder. We help patients locate pharmacies that currently have their medication available, saving you the frustration of calling around to pharmacy after pharmacy.
Independent pharmacies sometimes have stock when big chains don't. They may also have more flexibility to order directly from different wholesalers. Don't limit your search to CVS and Walgreens — try the smaller pharmacies in your area.
If Acyclovir is truly unavailable, your doctor may be able to switch you to a similar medication. Valacyclovir (Valtrex) is a prodrug that converts to Acyclovir in your body and is often easier to find. Famciclovir (Famvir) is another option in the same drug class. Both work similarly and are widely available as generics.
Read our full guide on alternatives to Acyclovir to learn more about your options.
If your pharmacy is out of stock, ask them to place a special order. Many pharmacies can get medications within 1-2 business days through their distributor. This isn't always possible during a widespread shortage, but it's worth asking.
If you take Acyclovir for suppressive therapy (like daily use for genital herpes), ask your doctor for a 90-day prescription. This means fewer refill trips and less chance of running into stock issues. Mail-order pharmacies often have better inventory for maintenance medications.
One silver lining: Acyclovir is relatively affordable as a generic medication. Without insurance, the average retail price is about $70 to $105 for 60 tablets of 400 mg. However, with a discount card from SingleCare or GoodRx, you can often pay as little as $8 to $15 for the same quantity.
If cost is a concern, check out our guide on how to save money on Acyclovir in 2026.
Finding Acyclovir shouldn't be this hard — but in 2026, supply challenges, manufacturing limitations, and rising demand have made it a reality for many patients. The most important thing is to not go without your medication. Whether you use Medfinder to track down a pharmacy with stock, ask your doctor about alternatives like Valacyclovir, or explore discount programs to make it more affordable, there are steps you can take today.
If you're a healthcare provider looking for resources to help your patients, visit our provider's guide to helping patients find Acyclovir.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.